|Day Low/High||0.57 / 0.62|
|52 Wk Low/High||0.84 / 4.32|
TheStreet's biotech columnist offers his own report card on biotech stocks.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ampio Pharmaceuticals Inc , where a total of 1,453 contracts have traded so far, representing approximately 145,300 underlying shares. That amounts to about 81.2% of AMPE's average daily trading volume over the past month of 179,045 shares.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a weak on high relative volume candidate
Ampio Pharma (AMPE) stock is sharply lower this afternoon following a phase 3 trial for its osteoarthritis pain treatment.
Ampio Pharmaceuticals (AMPE) shares are up over 10% after the company received Special Protocol Assessment from the FDA.
The Rosen Law Firm reminds purchasers of Ampio Pharmaceuticals, Inc.
The most recent short interest data has been released by the NASDAQ for the 04/30/2015 settlement date, which shows a 1,771,994 share decrease in total short interest for Ampio Pharmaceuticals Inc. , to 8,185,303, a decrease of 17.80% since 04/15/2015.
The Rosen Law Firm announces that it has filed a class action lawsuit on behalf of purchasers of Ampio Pharmaceuticals, Inc.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.